Qualifying an Excipient Supplier: What a Type IV DMF Tells You
How to read an excipient supplier's regulatory support: what a Type IV Drug Master File is, why most excipients have none, where pharmacopoeia grades and CEPs fit, and the checks that matter before you build a formulation around a supplier.
The short answer: A Type IV Drug Master File is a confidential file an excipient supplier lodges with the FDA so that a drug applicant can reference it. It is optional, the FDA never approves it, and most established excipients are supplied against a pharmacopoeia monograph with no DMF at all. When you qualify an excipient supplier, treat an active DMF as one useful signal, and put more weight on four things: the exact grade, the manufacturing site, the supplier's GMP system for excipients, and whether you have a second source.
Excipients get less scrutiny in sourcing than active ingredients, and cause a surprising share of the trouble. A change of filler grade can shift dissolution. A lubricant from a different site can change tablet hardness. A trace impurity in a common excipient can put nitrosamines into a finished product. The regulatory paperwork for excipients is also lighter and less uniform than for APIs, so it is easy to read too much or too little into it.
What a Type IV DMF is
The FDA accepts several types of Drug Master File. Type II covers active substances. Type IV covers excipients, colourants, flavours, essences, and the materials used to prepare them. The file holds the supplier's confidential manufacturing and control information. A drug applicant never sees it; the supplier issues a Letter of Authorization, and the FDA reads the file when it reviews the application that references it.
Three points are regularly misunderstood:
- A DMF is not an approval. The FDA neither approves nor rejects a DMF. "Active" means the file is open and its holder is keeping it up to date, so it can be referenced.
- A DMF is optional. Nothing obliges an excipient maker to file one.
- A DMF is specific. It covers the material the holder described, made at the site and by the process it described. A different grade from the same company may not be covered.
On the FDA's current list there are 2,346 active Type IV files held by 651 organisations. Only about a third of them name a single substance. The rest are branded blends, film-coating systems, capsule shells and flavours identified by a product code. You can browse the substances, and who holds a file for each, in the excipient directory.
Why most excipients have no DMF
For a well-established excipient, the usual route is simpler: the supplier certifies that the material meets a pharmacopoeia monograph (USP-NF, Ph. Eur., JP), and the applicant describes the excipient in its own application by reference to that monograph. Lactose, microcrystalline cellulose and magnesium stearate are bought this way every day.
A DMF earns its place when there is something the supplier will not disclose to customers:
- Novel excipients, with no monograph and no history of use at the proposed level or route. Their safety has to be supported in the application, and the supplier's data usually sits in a DMF.
- Functional or proprietary materials: absorption enhancers, cyclodextrin derivatives, lipids for injectables, modified-release polymers. Salcaprozate sodium, the absorption enhancer used in oral peptide tablets, has 30 holders of an active Type IV file, more than any other excipient on the list.
- Co-processed excipients and coating systems, whose composition is the supplier's know-how.
So the absence of a DMF tells you little about a commodity excipient, and its presence tells you a great deal about a novel one.
Where pharmacopoeia grades and CEPs fit
The grade is the specification. The same substance is sold to different monographs and in different physical forms: particle size, viscosity, degree of substitution, hydrate. A formulation is developed around one of them. Record the grade your development batches used, and qualify the supplier for that grade, not for the substance in general. In our directory the "filed as" column shows the grade each holder named in its filing, because that is the only place it appears.
In Europe, a CEP can do the DMF's job. An excipient with a Ph. Eur. monograph can hold an EDQM Certificate of Suitability, which confirms the monograph is able to control that supplier's material. Gelatin and other animal-derived excipients often carry a CEP for TSE risk specifically. A CEP is not a GMP certificate, and its holder is not always the manufacturer.
The FDA's Inactive Ingredient Database lists excipients used in approved products, with the route and the maximum amount. It is the first place to check whether your excipient, at your level and by your route, has precedent. An excipient used above its listed level is treated, in effect, as novel.
What to check before you commit
- Grade and specification. Agree a specification that includes the functional attributes your process depends on, not only the monograph tests. Monographs are written to identify and control purity; they often say nothing about the property that makes your formulation work.
- The manufacturing site. Ask where the material is made and whether the supplier is the manufacturer or a distributor. A change of site is a change you need to hear about in advance.
- Excipient GMP. Excipient makers are not inspected the way API makers are. Look for certification to an excipient GMP standard (EXCiPACT or the IPEC-PQG guide), and for EU products carry out the formalised risk assessment that determines the appropriate GMP for each excipient.
- Change notification. A quality agreement should oblige the supplier to tell you before it changes site, process, raw-material source or specification. For excipients this is where most unpleasant surprises come from.
- Impurity questions. Ask for statements on nitrosamine risk (nitrite content matters in common fillers and disintegrants), elemental impurities, residual solvents, and animal origin.
- Regulatory support for your market. If you need to reference a DMF, confirm it is active and that the holder will issue a Letter of Authorization for your application. If you rely on a monograph, confirm the certificate of analysis is against the edition you cite.
- A second source. Functional excipients are often single-sourced by habit. Check how many organisations support the material at all before you design around it.
How to screen holders quickly
Start from the substance. The excipient directory lists each excipient named in an active Type IV filing, with every holder, the DMF number, the grade as filed and the submission date, and any valid CEPs for the same substance. From a holder you can open its company profile to see its other filings, its registered manufacturing sites and their FDA inspection outcomes.
Keep the limits in mind. The list shows who has filed, not who can supply. Many capable excipient manufacturers appear nowhere on it, because they sell against a monograph. And an active file says nothing about price, capacity or lead time.
Frequently asked questions
What is a Type IV DMF? A Type IV Drug Master File is a confidential submission to the US FDA covering an excipient, colourant, flavour or essence, or a material used to prepare one. A drug applicant references it with the holder's Letter of Authorization, and the FDA reviews it as part of that application.
Does an excipient need a DMF? No. A DMF is optional. Most established excipients are supplied against a pharmacopoeia monograph and described in the drug application directly. A DMF is common for novel, functional or proprietary excipients whose details the supplier keeps confidential.
Is an active Type IV DMF an FDA approval of the excipient? No. The FDA does not approve or disapprove a DMF. "Active" means the file is open and maintained, so it can be referenced. The excipient is assessed in the context of each drug application that uses it.
What is a novel excipient? An excipient with no established use in an approved product, or one used at a higher level or by a different route than before. Its safety must be supported in the drug application, which usually means more data and a supplier DMF.
How is excipient GMP different from API GMP? Excipient manufacturers are not routinely inspected by drug regulators as API manufacturers are. Assurance comes from the drug manufacturer's own supplier qualification, supported by excipient GMP standards such as EXCiPACT and the IPEC-PQG guide and, for the EU, a formalised risk assessment for each excipient.
Looking for who supports a particular excipient? Browse the excipient directory, or ask the Sourcing Desk to screen suppliers for the grade you need.
Ready to Transform Your Pharma Intelligence?
See how PharmaTek combines clinical trial, company, regulatory, and competitive context
Start free trial